Novo Nordisk | NVO - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
ANI Pharmaceuticals USD 39.84M 1.13M 2026-06
Aurora Cannabis CAD -10.03M 25.76M 2026-03
Bausch Health Companies USD 776M 287M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Canopy Growth CAD -27.47M 14.81M 2026-03
Corcept Therapeutics USD 41.3M 90.9M 2026-06
Drreddys Laboratories INR 829M 13.5B 2026-03
Eli Lilly USD 12.46B 2.68B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Merck USD 840M 2.72B 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Novartis USD 4.75B 515M 2026-06
Novo Nordisk DKK 33.76B 25.86B 2026-06
Novo Nordisk DKK 5.25B 54.37B 2026-06
Pacira USD 9.96M 5.33M 2026-06
Perrigo USD 23.5M 10.1M 2026-06
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 52.52M 22.97M 2026-06
Sanofi EUR 2.38B 449M 2026-06
Supernus Pharmaceuticals USD -21.04M 14.21M 2026-06
Zoetis USD 1.12B 256M 2026-06